Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxepin hydrochloride
Drug ID BADD_D00721
Description Doxepin is a psychotropic agent with antidepressant and anxiolytic properties.[T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture.[T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine].[L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.[L5974]
Indications and Usage - Indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus [L1344].
Marketing Status Prescription; Discontinued
ATC Code D04AX01; N06AA12
DrugBank ID DB01142
KEGG ID D00814
MeSH ID D004316
PubChem ID 6419921
TTD Drug ID D06FES
NDC Product Code 70518-2401; 0527-4066; 43353-329; 70518-3005; 23155-796; 55700-917; 49884-217; 49884-219; 55801-527; 68071-2314; 60429-969; 42291-247; 0378-8117; 71921-162; 70756-426; 45865-775; 10267-5059; 71921-165; 42847-103; 16714-132; 70518-2468; 69315-159; 50090-3952; 43353-331; 51672-4217; 23155-795; 59746-704; 70756-428; 55700-768; 46708-639; 16714-135; 0378-8130; 0378-5391; 63629-2181; 0378-4250; 23155-797; 59651-175; 27241-168; 59651-174; 0527-4063; 55700-783; 23155-794; 62332-640; 42847-106; 62332-637; 54838-512; 59651-177; 68071-4464; 0378-1049; 45865-103; 69238-1173; 69315-160; 27241-167; 55289-370; 67763-117; 51079-438; 42806-529; 71205-534; 27241-171; 70518-2984; 69238-1171; 46438-0043; 70518-3360; 44183-106; 0378-5390; 0904-7052; 68071-5179; 0904-7053; 51927-0159; 10267-5061; 0378-6410; 55801-529; 70518-2949; 45865-968; 68071-5260; 71921-164; 63629-5033; 46708-637; 71335-2028; 72789-072; 55801-530; 0904-7055; 50090-5286; 49884-221; 10267-5060; 0378-8123; 69238-1166; 70518-3327; 0378-3125; 69238-1172; 63629-2182; 0904-7054; 51079-651; 60429-966; 16714-134; 0527-4065; 68071-2356; 42806-530; 70518-3017; 70518-2274; 60432-651; 60429-970; 71335-1770; 68788-7731; 71554-006; 59651-176; 71335-1704; 71335-1665; 46708-640; 49884-220; 16714-133; 38779-0218; 62332-639; 27241-169; 49884-222; 55801-528; 62332-645; 70518-3374; 60429-967; 70518-3020; 51672-4220; 46708-645; 59746-701; 59746-703; 35356-650; 50090-0278; 59746-702; 46708-638; 63629-2180; 70518-0386; 10267-5063; 0378-5375; 27241-170; 72189-161; 71335-0072; 72640-003; 63629-3221; 70756-425; 72789-220; 70518-2371; 16714-136; 51672-4219; 71921-163; 71335-1450; 70756-427; 0395-8135; 49452-2692; 17337-0513; 62991-3029; 0378-4810; 0378-4811; 42806-533; 67651-0309; 0527-4062; 70518-2519; 69315-161; 51079-436; 67651-0308; 70756-424; 10267-5062; 71335-0642; 62332-638; 0527-4064; 51672-4221; 55700-928; 51552-0982; 59651-173; 51672-4218; 47621-063; 71921-166; 49884-218; 69315-162; 70518-3314; 60429-968; 71205-610; 70518-3310; 69238-1170; 69315-163; 59746-700; 51927-2227; 44183-103; 69315-158; 51079-437; 71335-1941
Synonyms Doxepin | Deptran | Desidox | Doneurin | Doxepia | Doxepin beta | Doxepin Hydrochloride | Hydrochloride, Doxepin | Doxepin Hydrochloride, Cis-Trans Isomer Mixture (approximately 1:5) | Doxepin-RPh | Doxepin RPh | Espadox | Mareen | Novo-Doxepin | Novo Doxepin | Prudoxin | Quitaxon | Sinequan | Sinquan | Zonalon | Xepin | Aponal | Apo-Doxepin | Apo Doxepin | ApoDoxepin
Chemical Information
Molecular Formula C19H22ClNO
CAS Registry Number 1229-29-4
SMILES CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Aphthous ulcer07.05.06.002--Not Available
Asthenia08.01.01.001--Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Breast enlargement21.05.04.001--Not Available
Chills15.05.03.016; 08.01.09.001--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Diarrhoea07.02.01.001--
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.007--
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Eosinophilia01.02.04.001--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Hallucination19.10.02.002--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperpyrexia08.05.02.002--Not Available
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.002--
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages